China’s Peijia Medical Ltd (HKG: 9996) announced first patient enrollment in a multi-center clinical study for its transcatheter edge-to-edge repair (TEER) system GeminiOne in China. The first operation went smoothly, with the whole device being manipulated for a mere 30 minutes. The prospective regulatory, multi-center, target value study is designed to assess the safety and efficacy of the product in moderate to severe degenerative mitral regurgitation.
Product Features and Design
The product features a unique design to achieve a longer clamping arm length while maintaining a smaller implant size and delivery system. In addition, it can reduce the complexity of the surgery, in terms of the independent valve leaf capture function, avoid the repeated locking and unlocking automatic locking mechanism during the surgery, and also can deal with the multi-angle release design of a wider range of anatomical structures.-Fineline Info & Tech
